CyFlow™ CD79a FITC
| Alternative Name: | IgA , MB-1, MB1 |
| Antibody: | Yes |
| Antigen: | CD79a |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | HM57 |
| Emission Maximum: | 518 nm |
| Excitation Maximum: | 490 to 495 nm |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | FITC |
| Isotype: | IgG1 |
| Laser: | Blue |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Chicken, Cow, Guinea pig, Horse, Human, Mouse, Opossum, Pig, Rabbit, Rat |
| Product number: | CV675949 |
For Research Use Only
| HLDA Workshop | HLDA V—WS Code BC cB018 HLDA VI—WS Code BP 193 HLDA VI—WS Code BP 89 HLDA VI—WS Code B B103 HLDA VI—WS Code B CD79.4 |
| Quantity | 100 tests |
| Volume | 0.4 mL |
| Immunogen | Synthetic peptide corresponding to amino acids 202-216 of human CD79a |
| Background Information | CD79a (Ig α, MB1) forms disulfide-linked heterodimer with CD79b (Ig β, B29). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with λ5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. At the plasma cell stage, CD79a is present as an intracellular component. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling. |
| Usage | The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests. |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| van Noesel CJ, van Lier RA, Cordell JL, Tse AG, van Schijndel GM, de Vries EF, Mason DY, Borst J: The membrane IgM‑associated heterodimer on human B cells is a newly defined B cell antigen that contains the protein product of the mb‑1 gene. J Immunol. 1991 Jun 1; 146(11):3881‑8. < PMID: 2033258 > | Mason DY, Cordell JL, Tse AG, van Dongen JJ, van Noesel CJ, Micklem K, Pulford KA, Valensi F, Comans-Bitter WM, Borst J, et al: The IgM‑associated protein mb‑1 as a marker of normal and neoplastic B cells. J Immunol. 1991 Dec 1; 147(11):2474‑82. < PMID: 1747162 > | Mason DY, van Noesel CJ, Cordell JL, Comans-Bitter WM, Micklem K, Tse AG, van Lier RA, van Dongen JJ: The B29 and mb‑1 polypeptides are differentially expressed during human B cell differentiation. Eur J Immunol. 1992 Oct; 22(10):2753‑6. < PMID: 1396979 > | Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J Clin Pathol. 1993 Apr; 46(4):334‑6. < PMID: 7684403 > | Jones M, Cordell JL, Beyers AD, Tse AG, Mason DY: Detection of T and B cells in many animal species using cross‑reactive anti‑peptide antibodies. J Immunol. 1993 Jun 15; 150(12):5429‑35. < PMID: 8515069 > | Mason DY, Cordell JL, Brown MH, Borst J, Jones M, Pulford K, Jaffe E, Ralfkiaer E, Dallenbach F, Stein H, et al.: CD79a: a novel marker for B‑cell neoplasms in routinely processed tissue samples. Blood. 1995 Aug 15; 86(4):1453‑9. < PMID: 7632952 > | Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland Publishing Inc, New York. 1997; 1‑1342. < NLM ID: 9712219 > | Bannish G, Fuentes-Pananá EM, Cambier JC, Pear WS, Monroe JG: Ligand‑independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med. 2001 Dec 3; 194(11):1583‑96. < PMID: 11733573 > | Pike KA, Iacampo S, Friedmann JE, Ratcliffe MJ: The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B cell development. J Immunol. 2004 Feb 15; 172(4):2210‑8. < PMID: 14764688 > | Fuentes-Pananá EM, Bannish G, Shah N, Monroe JG: Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre‑B cell antigen receptor‑dependent processes. J Immunol. 2004 Jul 15; 173(2):1000‑11. < PMID: 15240688 > | Fuentes-Pananá EM, Bannish G, van der Voort D, King LB, Monroe JG: Ig alpha/Ig beta complexes generate signals for B cell development independent of selective plasma membrane compartmentalization. J Immunol. 2005 Feb 1; 174(3):1245‑52. < PMID: 15661879 > | Fuentes-Pananá EM, Bannish G, Karnell FG, Treml JF, Monroe JG: Analysis of the individual contributions of Igalpha (CD79a)‑ and Igbeta (CD79b)‑mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation. J Immunol. 2006 Dec 1; 177(11):7913‑22. < PMID: 17114463 > | Faldyna M, Samankova P, Leva L, Cerny J, Oujezdska J, Rehakova Z, Sinkora J: Cross‑reactive anti‑human monoclonal antibodies as a tool for B‑cell identification in dogs and pigs. Vet Immunol Immunopathol. 2007 Sep 15; 119(1‑2):56‑62. < PMID: 17673300 >